Fuente: Prohibición Partners Lugar: Uncategorized Cannabis telemedicine has become the dominant access channel in the world’s largest medical cannabis markets, but also their Achilles heel. 



Poland’s experience, where a single regulatory intervention halved dispensing volumes in weeks, only for the market to stage a full recovery over the following 12 months, offers the most data-rich case study available of what happens when telemedicine access is disrupted. 



For investors, operators, and policymakers watching Germany, Australia, and the UK navigate similar tensions, it is essential reading.



Telemedicine Transformed Cannabis Access — Then Became a Target



The growth story of medical cannabis in Europe over the past five years is, in large part, a telemedicine story. Digital platforms connecting patients with willing prescribers dismantled the two biggest barriers to access: geography and physician reluctance. Patients in rural areas without a sympathetic local doctor could consult remotely. The friction of booking, travelling, and sitting in a waiting room was replaced by online questionnaires and video calls — sometimes lasting only minutes.



In Poland, telemedicine-driven platforms helped push annual dispensing volumes from around 1 tonne in 2021 to nearly 5 tonnes by late 2023. In Germany, which became Europe’s largest medical cannabis market after reclassifying cannabis outside its narcotics law in April 2024, telemedicine platforms have driven a surge in imports so significant that authorities temporarily suspended new import licences. In Australia, the model fuelled one of the fastest patient ramps in global cannabis history.



In each of these markets, regulators and media began questioning whether telemedicine was being used to access cannabis recreationally under the cover of a medical framework. Reports of minimal clinical oversight, aggressive platform marketing, and prescriptions issued without meaningful consultation fed a backlash that, in Poland’s case, led to decisive government action.



Understanding the dynamics of cannabis telemedicine — the access it enables, the vulnerabilities it creates, and the market impact when it is restricted — has become one of the most commercially significant questions in the global cannabis industry.



Poland: The Natural Experiment



Poland’s medical cannabis market provided something no other country has yet offered: a complete, data-documented cycle of telemedicine-driven growth, regulatory shock, and market recovery.



The timeline is now well established. In November 2024, Polish authorities required patients to attend in-person consultations for medical cannabis prescriptions, effectively ending the telemedicine-driven model that had powered the market’s rapid expansion. The stated rationale centred on concerns about prescription abuse and insufficient clinical oversight — criticisms that echoed debates in Germany and Australia.



The market impact was immediate and severe. Monthly prescriptions collapsed from approximately 68,000 in October 2024 to around 28,000 by December — a decline of more than half in just two months. Dispensing volumes followed a similar trajectory.



What makes Poland’s experience uniquely valuable is not the crash. It is what came next.



The Recovery: Professionalisation, Not Regression



The narrative that might have been expected — a market permanently diminished by regulatory intervention — did not materialise. Instead, Poland’s medical cannabis sector adapted, restructured, and ultimately recovered its pre-ban volume levels within 12 months.



The recovery was not immediate. The first quarter of 2025 remained materially depressed. But volumes accelerated through the middle of the year, and by October 2025, monthly dispensing had surpassed the pre-ban peak for the first time. December 2025 set a new all-time high.



Full-year 2025 figures tell the story clearly: Polish pharmacies dispensed approximately 5,450 kilograms of dried cannabis flower, a 12% increase over 2024 — a year that included the pre-ban peak months.



Critically, the recovery was driven by structural adaptation rather than a return to the status quo. The loosely regulated telemedicine operations that had driven earlier growth were largely replaced by more structured clinic models. Some operators deployed prescribers to temporary physical locations in smaller cities, partially recreating the geographic access that telemedicine had provided. Others established permanent clinics with more rigorous consultation processes. The market professionalised under pressure.



This pattern matters enormously for other markets facing similar regulatory scrutiny. The Poland data suggests that telemedicine restrictions do not necessarily destroy demand — but they do reshape supply chains, change the economics of patient acquisition, and impose a significant, if temporary, disruption.



The Price Story Hidden Inside the Volume Recovery



Volume recovery, however, is only half the picture. Beneath the headline growth figure, Poland’s market underwent a fundamental pricing shift that has significant implications for operators and investors.



Full-year 2025 revenue fell to approximately PLN 253 million (roughly €60 million) — a decline of around 19% from 2024’s peak. The average price per gram dropped approximately 28% year-on-year, from around 65 PLN to 47 PLN per gram.



In other words, the market is moving substantially more product for substantially less money. Operators who survived the telemedicine ban and rebuilt their patient bases are now competing in a market where margins have compressed significantly. The volume recovery, while real, has not been accompanied by a revenue recovery.



This dynamic — rising volumes, falling revenues — is a pattern that investors in cannabis markets globally should watch carefully. It suggests that the post-telemedicine market structure may be fundamentally different from the one that preceded it, with implications for company valuations, market entry decisions, and competitive strategy.



The full pricing dynamics, including monthly granularity across 84 months of data, are available in the Poland Medical Cannabis Market Review 2026.



Why This Matters Now: Germany Is Following Poland’s Playbook



Poland’s experience would be a compelling case study in isolation. What makes it urgent is that Europe’s largest medical cannabis market appears to be heading down a similar path.



In October 2025, the German Federal Cabinet approved amendments to the Medical Cannabis Act (MedCanG) that would ban remote prescribing and mail-order dispensing of medical cannabis. Under the proposed legislation, initial prescriptions would require an in-person consultation, with follow-up prescriptions permitted via telemedicine only if the patient has been seen in person within the previous four quarters.



The parallels with Poland’s 2024 intervention are striking: the same concerns about telemedicine-driven overprescribing, the same political framing around patient safety, and the same industry warnings about reduced access — particularly for patients in rural areas.



Germany’s situation carries even higher commercial stakes. The market is estimated to be worth around €670 million, with imports surging through 2025 to the point where authorities suspended new import licences. Industry estimates suggest that only around 10-13% of total cannabis demand in Germany is currently served through medical channels, indicating significant room for continued growth — if the regulatory environment allows it.



The bill is expected to be finalised in the first half of 2026. Depending on its final form, the impact on Germany’s medical cannabis supply chain — from telemedicine platforms to pharmacies to importers — could be substantial.



Australia, too, faces mounting pressure around telemedicine-driven prescribing, with political scrutiny increasing through 2025 and 2026.



For operators and investors in these markets, Poland’s granular monthly data — showing the precise scale and duration of disruption, the shape of recovery, and the structural changes that followed — represents the closest available evidence base for modelling their own risk scenarios.



What the Data Shows: Lessons for the Industry



Poland’s 84-month dataset, spanning January 2019 to December 2025, offers several takeaways that apply across any market where cannabis telemedicine is under regulatory pressure.



Demand survived the shock. The telemedicine ban did not eliminate patient demand. It displaced it temporarily and restructured how it was served. This suggests that in markets with genuine patient need, regulatory restrictions on access channels slow growth rather than reversing it.



Recovery takes time. The full volume recovery took approximately 12 months. Any market modelling regulatory risk from telemedicine restrictions should factor in a multi-quarter disruption period, not a brief blip.



Professionalisation is the adaptation mechanism. The post-ban market structure in Poland is characterised by higher clinical standards and more robust patient-prescriber relationships than the telemedicine-era model. Markets that proactively professionalise their telemedicine offerings may be able to mitigate — or avoid — the kind of regulatory intervention Poland experienced.



Price compression is a structural consequence. The shift from a telemedicine-dominated model to a clinic-based model appears to have coincided with significant price competition. Operators should model the revenue impact of post-restriction price dynamics, not just volume recovery.



Data matters. Poland is now the only major European market where the complete telemedicine shock-and-recovery cycle has been documented with granular monthly data from official government sources. For boards, investors, and regulatory affairs teams building scenarios around Germany, Australia, or other markets, this dataset is difficult to replicate from any other source.







Access the Full Dataset



The Poland Medical Cannabis Market Review 2026 is a two-part package covering the complete market through full-year 2025, with three-scenario forecasts for 2026–2027:




Written report (PDF): Market size and growth trajectory, the telemedicine ban shock and recovery, pricing dynamics, sales revenue analysis, and strategic implications. Written for board-level and investor audiences.



Interactive Excel workbook: 10 tabs, hundreds of live formulas, 84 months of data (January 2019 – December 2025) across 10+ metrics per month. Every calculated value is a live formula traceable to government source data — not a static spreadsheet.




Available as a standalone report and data package (£399) or with a two-hour market intelligence briefing from a senior Prohibition Partners analyst (£1,099).



View the report →
The post Cannabis Telemedicine: What Poland’s Market Crash and Recovery Tells Us About Regulatory Risk appeared first on Prohibition Partners.